NEW YORK (GenomeWeb) – Circulogene announced today that it has signed a license agreement for its molecular cancer diagnostic technology with Turkish lab Circulogene Saglik, a subsidiary of GGT Global Genetik.
Under the terms of the deal, Circulogene's liquid biopsy technology — which enriches tumor DNA from small volumes of blood for next-generation sequencing-based analysis — will be exclusively licensed to Circulogene Saglik for use in Turkey and the surrounding regions, including parts of Europe, Africa, the Middle East, Armenia, Azerbaijan, Belarus, Georgia, Kazakstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine, and Uzbekistan.
Additional terms were not disclosed.
"This agreement aligns strongly with our aggressive growth and revenue strategy, expanding our laboratory's testing capabilities and availability internationally," Circulogene CEO Mike Mullen said in a statement.
In November, Circulogene began offering microsatellite instability biomarker testing for multiple cancer types.